Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | SDCBP | O00560 | 4/20 | 0.72 |
| ▸ | SDC2 | P34741 | 4/20 | 0.72 |
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.64 |
| ▸ | THRB | P10828 | 1/20 | 0.64 |
| ▸ | STAT3 | P40763 | 1/20 | 0.63 |
| ▸ | NPC1 | O15118 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4203635 | 1.00 | MAPT (1.00) | MAPTALOX15SMN1; SMN2SDCBPSDC2 | |
| SCHEMBL20014176 | 0.92 | MAPT (0.85) | MAPTALOX15SMN1; SMN2SDCBPSDC2 | |
| SCHEMBL825646 | 0.89 | MAPT (0.80) | MAPTALOX15SMN1; SMN2SDCBPSDC2 | |
| SCHEMBL18360802 | 0.88 | MAPT (0.77) | MAPTALOX15SMN1; SMN2SDCBPSDC2 | |
| SCHEMBL16602261 | 0.87 | MAPT (0.76) | MAPTALOX15SMN1; SMN2SDCBPSDC2 | |
| SCHEMBL23092765 | 0.86 | MAPT (0.76) | MAPTALOX15SMN1; SMN2SDCBPSDC2 | |
| SCHEMBL29715263 | 0.86 | MAPT (0.76) | MAPTALOX15SMN1; SMN2SDCBPSDC2 | |
| SCHEMBL23092767 | 0.86 | MAPT (0.76) | MAPTALOX15SMN1; SMN2SDCBPSDC2 | |
| SCHEMBL20365450 | 0.85 | MAPT (0.74) | MAPTALOX15SMN1; SMN2SDCBPSDC2 | |
| SCHEMBL12643502 | 0.85 | MAPT (0.74) | MAPTALOX15SMN1; SMN2SDCBPSDC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5698579-A | INHIBITOR OF TUMOR NECROSIS FACTOR | CELGENE CORPORATION (US) | 1997-12-16 | — | — | US | claimed |
| US-20240262792-A1 | USP30 INHIBITORS AND USES THEREOF | VINCERE BIOSCIENCES, INC. | 2024-08-08 | — | — | US | disclosed |
| US-11845724-B2 | USP30 inhibitors and uses thereof | VINCERE BIOSCIENCES, INC. (US) | 2023-12-19 | — | — | US | disclosed |
| EP-4275759-A2 | QUINOLINE DERIVATIVES AS CHROMOBOX (CBX) PROTEIN INHIBITORS FOR TREATING CANCER | Dana-Farber Cancer Institute, Inc. (US) | 2023-11-15 | — | — | EP | disclosed |
| EP-3515449-B1 | QUINOLINE DERIVATIVES AS CHROMOBOX (CBX) PROTEIN INHIBITORS FOR TREATING CANCER | DANA FARBER CANCER INST INC (US) | 2023-07-12 | — | — | EP | disclosed |
| US-20220315531-A1 | USP30 INHIBITORS AND USES THEREOF | VINCERE BIOSCIENCES, INC. | 2022-10-06 | — | — | US | disclosed |
| EP-4028385-A1 | USP30 INHIBITORS AND USES THEREOF | Vincere Biosciences, Inc. (US) | 2022-07-20 | — | — | EP | disclosed |
| EP-2555769-B1 | METHODS FOR TREATING RESPIRATORY VIRAL INFECTION | AMGEN EUROPE GMBH (CH) | 2022-01-12 | — | — | EP | disclosed |
| US-20210372959-A1 | Nanopore Method for Identifying Single Amino Acid in Oligopeptides | UNIVERSITY OF SOUTH CAROLINA (US) | 2021-12-02 | — | — | US | disclosed |
| WO-2021050992-A1 | USP30 INHIBITORS AND USES THEREOF | VINCERE BIOSCIENCES, INC. (US) | 2021-03-18 | — | — | WO | disclosed |
| WO-2003097040-A1 | METHODS AND COMPOSITIONS USING SELECTIVE CYTOKINE INHIBITORY DRUGS FOR TREATMENT AND MANAGEMENT OF CANCERS AND OTHER DISEASES | CELGENE CORPORATION (US) | 2003-11-27 | — | — | WO | disclosed |
| WO-2003086373-A1 | METHODS FOR IDENTIFICATION OF MODULATORS OF ANGIOGENESIS, COMPOUNDS DISCOVERED THEREBY, AND METHODS OF TREATMENT USING THE COMPOUNDS | CELGENE CORPORATION (US) | 2003-10-23 | — | — | WO | disclosed |
| WO-2003087333-A2 | MODULATION OF STEM AND PROGENITOR CELL DIFFERENTIATION, ASSAYS, AND USES THEREOF | CELGENE CORPORATION (US) | 2003-10-23 | — | — | WO | disclosed |
| EP-1242082-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF ATHEROSCLEROSIS, RESTENOSIS AND RELATED DISORDERS | CELGENE CORPORATION (US) | 2002-09-25 | — | — | EP | disclosed |
| US-20020054899-A1 | Methods and compositions for the prevention and treatment of atherosclerosis, restenosis and related disorders | CELGENE CORP. | 2002-05-09 | — | — | US | disclosed |
| WO-2001043743-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF ATHEROSCLEROSIS, RESTENOSIS AND RELATED DISORDERS | CELGENE CORP. (US) | 2001-06-21 | — | — | WO | disclosed |
| US-6200987-B1 | ADMINISTERING AS TUMOR NECROSIS FACTOR INHIBITORS; CACHEXIA, ENDOTOXIN SHOCK; RETROVIRUS VIRICIDES | CELGENE CORPORATION | 2001-03-13 | — | — | US | disclosed |
| US-6075041-A | TUMOR NECROSIS FACTOR | CELGENE CORPORATION (US) | 2000-06-13 | — | — | US | disclosed |
| US-5877200-A | Cyclic amides | CELGENE CORPORATION (US) | 1999-03-02 | — | — | US | disclosed |
| US-5698579-A | INHIBITOR OF TUMOR NECROSIS FACTOR | CELGENE CORPORATION (US) | 1997-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11845724-B2 | USP30 inhibitors and uses thereof | USP30, USP28, USP1 | MAPT 2434/4885ALOX15 4347/4885SMN1; SMN2 1580/4885 |
| US-20220315531-A1 | USP30 INHIBITORS AND USES THEREOF | USP30, USP28, USP1 | MAPT 2434/4885ALOX15 4347/4885SMN1; SMN2 1580/4885 |
| US-20240262792-A1 | USP30 INHIBITORS AND USES THEREOF | USP30, USP28, USP1 | MAPT 2434/4885ALOX15 4347/4885SMN1; SMN2 1580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.